Publications

  1. Harikumar KG, Cawston EE, Lam PC, Patil A, Orry A, Henke BR, Abagyan R, Christopoulos A, Sexton PM, Miller LJ. Molecular basis for benzodiazepine agonist action at the type 1 cholecystokinin receptor. J Biol Chem. 2013 Jun 10. [Epub ahead of print] 2329447
    View PubMed
  2. Lomberk G, Grzenda A, Mathison A, Escande C, Zhang JS, Calvo E, Miller LJ, Iovanna J, Chini EN, Fernandez-Zapico ME, Urrutia R. Kruppel-like Factor 11 Regulates the Expression of Metabolic Genes via an Evolutionarily Conserved Protein-Interaction Domain Functionally Disrupted in Maturity Onset Diabetes of the Young. J Biol Chem. 2013 Apr 15. [Epub ahead of print] 2317224
    View PubMed
  3. Harikumar KG, Potter RM, Patil A, Echeveste V, Miller LJ. Membrane cholesterol affects stimulus-activity coupling in type 1, but not type 2, CCK receptors: use of cell lines with elevated cholesterol. Lipids. 2013 Mar; 48(3):231-44. Epub 2013 Jan 11. 2295667
    View PubMed
  4. Koole C, Pabreja K, Savage EE, Wootten D, Furness SG, Miller LJ, Christopoulos A, Sexton PM. Recent advances in understanding GLP-1R (glucagon-like peptide-1 receptor) function. Biochem Soc Trans. 2013 Feb 1; 41(1):172-9. 2299893
    View PubMed
  5. Miller LJ, Dong M. The orthosteric agonist-binding pocket in the prototypic class B G-protein-coupled secretin receptor. Biochem Soc Trans. 2013 Feb 1; 41(1):154-8. 2299546
    View PubMed
  6. Qi T, Dong M, Watkins HA, Wootten D, Miller LJ, Hay DL. Receptor activity-modifying protein-dependent impairment of calcitonin receptor splice variant Delta(1-47)hCT((a)) function. Br J Pharmacol. 2013 Feb; 168(3):644-57. 2300581
    View PubMed
  7. Dong M, Pinon DI, Miller LJ. Insights into the impact of phenolic residue incorporation at each position along secretin for receptor binding and biological activity. Regul Pept. 2013 Jan 10; 180:5-11. Epub 2012 Nov 08. 2282886
    View PubMed
  8. Miller LJ. Molecular basis of peptide activation of the GLP-1 receptor. Molecular Metabolism. 2013; 2(2):60-1. 2326380
  9. Wootten D, Simms J, Miller LJ, Christopoulos A, Sexton PM. Polar transmembrane interactions drive formation of ligand-specific and signal pathway-biased family B G protein-coupled receptor conformations. Proc Natl Acad Sci U S A. 2013; 110(13):5211-6. 2316305
  10. Dong M, Xu X, Ball AM, Makhoul JA, Lam PC, Pinon DI, Orry A, Sexton PM, Abagyan R, Miller LJ. Mapping spatial approximations between the amino terminus of secretin and each of the extracellular loops of its receptor using cysteine trapping. FASEB J. 2012 Dec; 26(12):5092-105. Epub 2012 Sep 10. 2269943
    View PubMed
  11. Harikumar KG, Wootten D, Pinon DI, Koole C, Ball AM, Furness SG, Graham B, Dong M, Christopoulos A, Miller LJ, Sexton PM. Glucagon-like peptide-1 receptor dimerization differentially regulates agonist signaling but does not affect small molecule allostery. Proc Natl Acad Sci U S A. 2012 Nov 6; 109(45):18607-12. Epub 2012 Oct 22. 2279320
    View PubMed
  12. Te JA, Dong M, Miller LJ, Bordner AJ. Predicting the effects of amino acid replacements in peptide hormones on their binding affinities for class B GPCRs and application to the design of secretin receptor antagonists. J Comput Aided Mol Des. 2012 Jul; 26(7):835-45. Epub 2012 May 11. 2244758
    View PubMed
  13. Cawston EE, Lam PC, Harikumar KG, Dong M, Ball AM, Augustine ML, Akgun E, Portoghese PS, Orry A, Abagyan R, Sexton PM, Miller LJ. Molecular basis for binding and subtype selectivity of 1,4-benzodiazepine antagonist ligands of the cholecystokinin receptor. J Biol Chem. 2012 May 25; 287(22):18618-35. Epub 2012 Mar 30. 2236746
    View PubMed
  14. Miller LJ, Dong M, Harikumar KG. Ligand binding and activation of the secretin receptor, a prototypic family B G protein-coupled receptor. Br J Pharmacol. 2012 May; 166(1):18-26. 2163821
    View PubMed
  15. Garcia GL, Dong M, Miller LJ. Differential determinants for coupling of distinct G proteins with the class B secretin receptor. Am J Physiol Cell Physiol. 2012 Apr 15; 302(8):C1202-12. Epub 2012 Jan 25. 2219774
    View PubMed
  16. Koole C, Wootten D, Simms J, Miller LJ, Christopoulos A, Sexton PM. Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) has a critical role in GLP-1 peptide binding and receptor activation. J Biol Chem. 2012 Feb 3; 287(6):3642-58. Epub 2011 Dec 06. 2228607
    View PubMed
  17. Koole C, Wootten D, Simms J, Savage EE, Miller LJ, Christopoulos A, Sexton PM. Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) differentially regulates orthosteric but not allosteric agonist binding and function. J Biol Chem. 2012 Feb 3; 287(6):3659-73. Epub 2011 Dec 06. 2228608
    View PubMed
  18. Cawston EE, Harikumar KG, Miller LJ. Ligand-induced internalization of the type 1 cholecystokinin receptor independent of recognized signaling activity. Am J Physiol Cell Physiol. 2012 Feb 1; 302(3):C615-27. Epub 2011 Nov 02. 2203565
    View PubMed
  19. Dong M, Pinon DI, Miller LJ. Site of action of a pentapeptide agonist at the glucagon-like peptide-1 receptor. Insight into a small molecule agonist-binding pocket. Bioorg Med Chem Lett. 2012 Jan 1; 22(1):638-41. Epub 2011 Oct 25. 2206687
    View PubMed
  20. Potter RM, Harikumar KG, Wu SV, Miller LJ. Differential sensitivity of types 1 and 2 cholecystokinin receptors to membrane cholesterol. J Lipid Res. 2012 Jan; 53(1):137-48. Epub 2011 Oct 21. 2201945
    View PubMed
  21. Ke J, Zhang C, Harikumar KG, Zylstra-Diegel CR, Wang L, Mowry LE, Miller LJ, Williams BO, Xu HE. Modulation of beta-catenin signaling by glucagon receptor activation. PLoS One. 2012; 7(3):e33676. Epub 2012 Mar 16. 2235853
    View PubMed
  22. Desai AJ, Miller LJ. Sensitivity of cholecystokinin receptors to membrane cholesterol content. Front Endocrinol (Lausanne). 2012; 3:123. Epub 2012 Oct 18. 2278580
    View PubMed
  23. Katchman BA, Antwi K, Hostetter G, Demeure MJ, Watanabe A, Decker GA, Miller LJ, Von Hoff DD, Lake DF. Quiescin sulfhydryl oxidase 1 promotes invasion of pancreatic tumor cells mediated by matrix metalloproteinases. Mol Cancer Res. 2011 Dec; 9(12):1621-31. Epub 2011 Oct 11. 2139063
    View PubMed
  24. Dong M, Te JA, Xu X, Wang J, Pinon DI, Storjohann L, Bordner AJ, Miller LJ. Lactam constraints provide insights into the receptor-bound conformation of secretin and stabilize a receptor antagonist. Biochemistry. 2011 Sep 27; 50(38):8181-92. Epub 2011 Aug 30. 2187716
    View PubMed
  25. Koole C, Wootten D, Simms J, Valant C, Miller LJ, Christopoulos A, Sexton PM. Polymorphism and ligand dependent changes in human glucagon-like peptide-1 receptor (GLP-1R) function: allosteric rescue of loss of function mutation. Mol Pharmacol. 2011 Sep; 80(3):486-97. Epub 2011 May 26. 2190907
    View PubMed
  26. Harikumar KG, Cawston EE, Miller LJ. Fluorescence polarization screening for allosteric small molecule ligands of the cholecystokinin receptor. Assay Drug Dev Technol. 2011 Aug; 9(4):394-402. Epub 2011 Mar 11. 2182134
    View PubMed
  27. Dong M, Lam PC, Pinon DI, Hosohata K, Orry A, Sexton PM, Abagyan R, Miller LJ. Molecular basis of secretin docking to its intact receptor using multiple photolabile probes distributed throughout the pharmacophore. J Biol Chem. 2011 Jul 8; 286(27):23888-99. Epub 2011 May 12. 2165311
    View PubMed
  28. Miller LJ, Chen Q, Lam PC, Pinon DI, Sexton PM, Abagyan R, Dong M. Refinement of glucagon-like peptide 1 docking to its intact receptor using mid-region photolabile probes and molecular modeling. J Biol Chem. 2011 May 6; 286(18):15895-907. Epub 2011 Mar 16. 2155534
    View PubMed
  29. Dong M, Le A, Te JA, Pinon DI, Bordner AJ, Miller LJ. Importance of each residue within secretin for receptor binding and biological activity. Biochemistry. 2011 Apr 12; 50(14):2983-93. Epub 2011 Mar 21. 2155710
    View PubMed
  30. Carrigan PE, Bingham JL, Srinvasan S, Brentnall TA, Miller LJ. Characterization of alternative spliceoforms and the RNA splicing machinery in pancreatic cancer. Pancreas. 2011 Mar; 40(2):281-8. 2135914
    View PubMed
  31. Fry BG, Winter K, Norman JA, Roelants K, Nabuurs RJ, van Osch MJ, Teeuwisse WM, van der Weerd L, McNaughtan JE, Kwok HF, Scheib H, Greisman L, Kochva E, Miller LJ, Gao F, Karas J, Scanlon D, Lin F, Kuruppu S, Shaw C, Wong L, Hodgson WC. Functional and structural diversification of the Anguimorpha lizard venom system. Mol Cell Proteomics. 2010 Nov; 9(11):2369-90. Epub 2010 Jul 14. 2130035
    View PubMed
  32. Dong M, Pinon DI, Bordner AJ, Miller LJ. Elucidation of the active conformation of the amino terminus of receptor-bound secretin using intramolecular disulfide bond constraints. Bioorg Med Chem Lett. 2010 Oct 15; 20(20):6040-4. Epub 2010 Aug 15. 2114905
    View PubMed
  33. Harikumar KG, Ball AM, Sexton PM, Miller LJ. Importance of lipid-exposed residues in transmembrane segment four for family B calcitonin receptor homo-dimerization. Regul Pept. 2010 Sep 24; 164(2-3):113-9. Epub 2010 Jun 10. 2101898
    View PubMed
  34. Koole C, Wootten D, Simms J, Valant C, Sridhar R, Woodman OL, Miller LJ, Summers RJ, Christopoulos A, Sexton PM. Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening. Mol Pharmacol. 2010 Sep; 78(3):456-65. Epub 2010 Jun 14. 2114987
    View PubMed
  35. Chen Q, Pinon DI, Miller LJ, Dong M. Spatial approximations between residues 6 and 12 in the amino-terminal region of glucagon-like peptide 1 and its receptor: a region critical for biological activity. J Biol Chem. 2010 Aug 6; 285(32):24508-18. Epub 2010 Jun 07. 2101930
    View PubMed
  36. Chen Q, Miller LJ, Dong M. Role of N-linked glycosylation in biosynthesis, trafficking, and function of the human glucagon-like peptide 1 receptor. Am J Physiol Endocrinol Metab. 2010 Jul; 299(1):E62-8. Epub 2010 Apr 20. 2101985
    View PubMed
  37. Dong M, Narang P, Pinon DI, Bordner AJ, Miller LJ. Refinement of the pharmacophore of an agonist ligand of the secretin receptor using conformationally constrained cyclic hexapeptides. Peptides. 2010 Jun; 31(6):1094-8. Epub 2010 Mar 07. 1990475
    View PubMed
  38. Kenakin T, Miller LJ. Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev. 2010 Jun; 62(2):265-304. Epub 2010 Apr 14. 1995565
    View PubMed
  39. Pioszak AA, Harikumar KG, Parker NR, Miller LJ, Xu HE. Dimeric arrangement of the parathyroid hormone receptor and a structural mechanism for ligand-induced dissociation. J Biol Chem. 2010 Apr 16; 285(16):12435-44. Epub 2010 Feb 19. 1999529
    View PubMed
  40. Harikumar KG, Akgun E, Portoghese PS, Miller LJ. Modulation of cell surface expression of nonactivated cholecystokinin receptors using bivalent ligand-induced internalization. J Med Chem. 2010 Apr 8; 53(7):2836-42. 1992883
    View PubMed
  41. Decker GA, Batheja MJ, Collins JM, Silva AC, Mekeel KL, Moss AA, Nguyen CC, Lake DF, Miller LJ. Risk factors for pancreatic adenocarcinoma and prospects for screening. Gastroenterol Hepatol (N Y). 2010 Apr; 6(4):246-54. 1996943
    View PubMed
  42. Korner M, Waser B, Reubi JC, Miller LJ. CCK2 receptor splice variant with intron 4 retention in human gastrointestinal and lung tumours. J Cell Mol Med. 2010 Apr; 14(4):933-43. 2102254
    View PubMed
  43. Korner M, Waser B, Reubi JC, Miller LJ. CCK(2) receptor splice variant with intron 4 retention in human gastrointestinal and lung tumours. J Cell Mol Med. 2010 Apr; 14(4):933-43. Epub 2009 Jul 20. 1953743
    View PubMed
  44. Dong M, Lam PC, Pinon DI, Orry A, Sexton PM, Abagyan R, Miller LJ. Secretin occupies a single protomer of the homodimeric secretin receptor complex: insights from photoaffinity labeling studies using dual sites of covalent attachment. J Biol Chem. 2010 Mar 26; 285(13):9919-31. Epub 2010 Jan 25. 1982468
    View PubMed
  45. Cawston EE, Miller LJ. Therapeutic potential for novel drugs targeting the type 1 cholecystokinin receptor. Br J Pharmacol. 2010 Mar; 159(5):1009-21. Epub 2009 Nov 18. 1974154
    View PubMed
  46. Harikumar KG, Simms J, Christopoulos G, Sexton PM, Miller LJ. Molecular basis of association of receptor activity-modifying protein 3 with the family B G protein-coupled secretin receptor. Biochemistry. 2009 Dec 15; 48(49):11773-85. 1972882
    View PubMed
  47. Chen Q, Pinon DI, Miller LJ, Dong M. Molecular basis of glucagon-like peptide 1 docking to its intact receptor studied with carboxyl-terminal photolabile probes. J Biol Chem. 2009 Dec 4; 284(49):34135-44. Epub 2009 Oct 08. 1967157
    View PubMed
  48. Dong M, Miller LJ. Effects of pH and temperature on photoaffinity labeling of Family B G protein-coupled receptors. Regul Pept. 2009 Nov 27; 158(1-3):110-5. Epub 2009 May 18. 1944235
    View PubMed
  49. Dong M, Cox RF, Miller LJ. Juxtamembranous region of the amino terminus of the family B G protein-coupled calcitonin receptor plays a critical role in small-molecule agonist action. J Biol Chem. 2009 Aug 14; 284(33):21839-47. Epub 2009 May 15. 1944254
    View PubMed
  50. Gao F, Harikumar KG, Dong M, Lam PC, Sexton PM, Christopoulos A, Bordner A, Abagyan R, Miller LJ. Functional importance of a structurally distinct homodimeric complex of the family B G protein-coupled secretin receptor. Mol Pharmacol. 2009 Aug; 76(2):264-74. Epub 2009 May 08. 1940672
    View PubMed
  51. Korner M, Miller LJ. Alternative splicing of pre-mRNA in cancer: focus on G protein-coupled peptide hormone receptors. Am J Pathol. 2009 Aug; 175(2):461-72. Epub 2009 Jul 02. 1950959
    View PubMed
  52. Dong M, Lam PC, Pinon DI, Abagyan R, Miller LJ. Elucidation of the molecular basis of cholecystokinin Peptide docking to its receptor using site-specific intrinsic photoaffinity labeling and molecular modeling. Biochemistry. 2009 Jun 16; 48(23):5303-12. 1942118
    View PubMed
  53. Akgun E, Korner M, Gao F, Harikumar KG, Waser B, Reubi JC, Portoghese PS, Miller LJ. Synthesis and in vitro characterization of radioiodinatable benzodiazepines selective for type 1 and type 2 cholecystokinin receptors. J Med Chem. 2009 Apr 9; 52(7):2138-47. 1931960
    View PubMed
  54. Zheng Y, Akgun E, Harikumar KG, Hopson J, Powers MD, Lunzer MM, Miller LJ, Portoghese PS. Induced association of mu opioid (MOP) and type 2 cholecystokinin (CCK2) receptors by novel bivalent ligands. J Med Chem. 2009 Jan 22; 52(2):247-58. 1915039
    View PubMed
  55. Harikumar KG, Miller LJ. Application of fluorescence resonance energy transfer techniques to establish ligand-receptor orientation. Methods Mol Biol. 2009; 552:293-304. 1946876
    View PubMed
  56. Harikumar KG, Miller LJ. Use of fluorescence indicators in receptor ligands. Methods Mol Biol. 2009; 552:279-91. 1946877
    View PubMed
  57. Simms J, Hall NE, Lam PH, Miller LJ, Christopoulos A, Abagyan R, Sexton PM. Homology modeling of GPCRs. Methods Mol Biol. 2009; 552:97-113. 1950513
    View PubMed
  58. Miller LJ. Informed development of drugs acting at family B G protein-coupled receptors. Ann N Y Acad Sci. 2008 Nov; 1144:203-9. 1915146
    View PubMed
  59. Harikumar KG, Miller LJ. Monitoring the state of cholecystokinin receptor oligomerization after ligand binding using decay of time-resolved fluorescence anisotropy. Ann N Y Acad Sci. 2008 Nov; 1144:21-7. 1915147
    View PubMed
  60. Miller LJ. G protein-coupled receptor structures, molecular associations, and modes of regulation. Ann N Y Acad Sci. 2008 Nov; 1144:1-5. 1915148
    View PubMed
  61. Dong M, Pinon DI, Miller LJ. Exploration of the endogenous agonist mechanism for activation of secretin and VPAC1 receptors using synthetic glycosylated peptides. J Mol Neurosci. 2008 Nov; 36(1-3):254-9. Epub 2008 Apr 12. 1915905
    View PubMed
  62. Harikumar KG, Morfis MM, Sexton PM, Miller LJ. Pattern of intra-family hetero-oligomerization involving the G-protein-coupled secretin receptor. J Mol Neurosci. 2008 Nov; 36(1-3):279-85. Epub 2008 Apr 10. 1915907
    View PubMed
  63. Harikumar KG, Happs RM, Miller LJ. Dimerization in the absence of higher-order oligomerization of the G protein-coupled secretin receptor. Biochim Biophys Acta. 2008 Nov; 1778(11):2555-63. Epub 2008 Jul 17. 1915751
    View PubMed
  64. Harikumar KG, Gao F, Pinon DI, Miller LJ. Use of multidimensional fluorescence resonance energy transfer to establish the orientation of cholecystokinin docked at the type A cholecystokinin receptor. Biochemistry. 2008 Sep 9; 47(36):9574-81. Epub 2008 Aug 13. 1898975
    View PubMed
  65. Wu SV, Harikumar KG, Burgess RJ, Reeve JR Jr, Miller LJ. Effects of cholecystokinin-58 on type 1 cholecystokinin receptor function and regulation. Am J Physiol Gastrointest Liver Physiol. 2008 Sep; 295(3):G641-7. 1902484
    View PubMed
  66. Gao F, Sexton PM, Christopoulos A, Miller LJ. Benzodiazepine ligands can act as allosteric modulators of the Type 1 cholecystokinin receptor. Bioorg Med Chem Lett. 2008 Aug 1; 18(15):4401-4. Epub 2008 Jun 20. 1894769
    View PubMed
  67. Dong M, Lam PC, Pinon DI, Sexton PM, Abagyan R, Miller LJ. Spatial approximation between secretin residue five and the third extracellular loop of its receptor provides new insight into the molecular basis of natural agonist binding. Mol Pharmacol. 2008 Aug; 74(2):413-22. Epub 2008 May 08. 1894771
    View PubMed
  68. Kumar M, Reeve JR Jr, Hu W, Miller LJ, Keire DA. The micelle-associated 3D structures of Boc-Y(SO3)-Nle-G-W-Nle-D-2-phenylethylester (JMV-180) and CCK-8(s) share conformational elements of a calculated CCK1 receptor-bound model. J Med Chem. 2008 Jul 10; 51(13):3742-54. Epub 2008 Jun 10. 1909464
    View PubMed
  69. Miller LJ, Gao F. Structural basis of cholecystokinin receptor binding and regulation. Pharmacol Ther. 2008 Jul; 119(1):83-95. Epub 2008 May 11. 1915852
    View PubMed
  70. Dong M, Gao F, Pinon DI, Miller LJ. Insights into the structural basis of endogenous agonist activation of family B G protein-coupled receptors. Mol Endocrinol. 2008 Jun; 22(6):1489-99. Epub 2008 Mar 27. 1894751
    View PubMed
  71. Korner MU, Hayes GM, Carrigan PE, Rehmann R, Miller LJ, Reubi JC. Wild-type and splice-variant secretin receptors in lung cancer: overexpression in carcinoid tumors and peritumoral lung tissue. Mod Pathol. 2008 Apr; 21(4):387-95. Epub 2008 Jan 25. 1902534
    View PubMed
  72. Bingham JL, Carrigan PE, Miller LJ, Srinivasan S. Extent and diversity of human alternative splicing established by complementary database annotation and microarray analysis. OMICS. 2008 Mar; 12(1):83-92. 1900642
    View PubMed
  73. Tokunaga H, Matsuura B, Dong M, Miller LJ, Ueda T, Furukawa S, Hiasa Y, Onji M. Mutational analysis of predicted intracellular loop domains of human motilin receptor. Am J Physiol Gastrointest Liver Physiol. 2008 Feb; 294(2):G460-6. Epub 2007 Nov 21. 1898959
    View PubMed
  74. Carrigan PE, Hentz JG, Gordon G, Morgan JL, Raimondo M, Anbar AD, Miller LJ. Distinctive heavy metal composition of pancreatic juice in patients with pancreatic carcinoma. Cancer Epidemiol Biomarkers Prev. 2007 Dec; 16(12):2656-63. 1867185
    View PubMed
  75. Harikumar KG, Lam PC, Dong M, Sexton PM, Abagyan R, Miller LJ. Fluorescence resonance energy transfer analysis of secretin docking to its receptor: mapping distances between residues distributed throughout the ligand pharmacophore and distinct receptor residues. J Biol Chem. 2007 Nov 9; 282(45):32834-43. Epub 2007 Sep 07. 1853405
    View PubMed
  76. Harikumar KG, Pinon DI, Miller LJ. Transmembrane segment IV contributes a functionally important interface for oligomerization of the Class II G protein-coupled secretin receptor. J Biol Chem. 2007 Oct 19; 282(42):30363-72. Epub 2007 Aug 28. 1846372
    View PubMed
  77. Hayes GM, Carrigan PE, Dong M, Reubi JC, Miller LJ. A novel secretin receptor splice variant potentially useful for early diagnosis of pancreatic carcinoma. Gastroenterology. 2007 Sep; 133(3):853-61. Epub 2007 Jun 20. 1841451
    View PubMed
  78. Miller LJ, Dong M, Harikumar KG, Gao F. Structural basis of natural ligand binding and activation of the Class II G-protein-coupled secretin receptor. Biochem Soc Trans. 2007 Aug; 35(Pt 4):709-12. 1841575
    View PubMed
  79. Lisenbee CS, Harikumar KG, Miller LJ. Mapping the architecture of secretin receptors with intramolecular fluorescence resonance energy transfer using acousto-optic tunable filter-based spectral imaging. Mol Endocrinol. 2007 Aug; 21(8):1997-2008. Epub 2007 May 15. 1841267
    View PubMed
  80. Dong M, Lam PC, Gao F, Hosohata K, Pinon DI, Sexton PM, Abagyan R, Miller LJ. Molecular approximations between residues 21 and 23 of secretin and its receptor: development of a model for peptide docking with the amino terminus of the secretin receptor. Mol Pharmacol. 2007 Aug; 72(2):280-90. Epub 2007 May 02. 1836899
    View PubMed
  81. Dong M, Ding XQ, Thomas SE, Gao F, Lam PC, Abagyan R, Miller LJ. Role of lysine187 within the second extracellular loop of the type A cholecystokinin receptor in agonist-induced activation. Use of complementary charge-reversal mutagenesis to define a functionally important interdomain interaction. Biochemistry. 2007 Apr 17; 46(15):4522-31. Epub 2007 Mar 24. 1818784
    View PubMed
  82. Hayes GM, Carrigan PE, Miller LJ. Serine-arginine protein kinase 1 overexpression is associated with tumorigenic imbalance in mitogen-activated protein kinase pathways in breast, colonic, and pancreatic carcinomas. Cancer Res. 2007 Mar 1; 67(5):2072-80. 1812324
    View PubMed
  83. Miller LJ, Dong M, Harikumar KG, Lisenbee CS. Biochemical and cell biological mechanisms of cholecystokinin receptor regulation. Curr Top Med Chem. 2007; 7(12):1166-72. 1836895
    View PubMed
  84. Decker GA, Leighton JA, Harrison ME, Nguyen CC, Das A, Pasha SF, Moss AA, Miller LJ. New technology, new complications: Pancreatitis complicating double-balloon enteroscopy. Gastroenterol. Hepatol. 2007; 3(12):920-2. 1975651
    View PubMed
  85. Harikumar KG, Dong M, Cheng Z, Pinon DI, Lybrand TP, Miller LJ. Transmembrane segment peptides can disrupt cholecystokinin receptor oligomerization without affecting receptor function. Biochemistry. 2006 Dec 12; 45(49):14706-16. 1794612
    View PubMed
  86. Korner M, Hayes GM, Rehmann R, Zimmermann A, Scholz A, Wiedenmann B, Miller LJ, Reubi JC. Secretin receptors in the human liver: expression in biliary tract and cholangiocarcinoma, but not in hepatocytes or hepatocellular carcinoma. J Hepatol. 2006 Dec; 45(6):825-35. Epub 2006 Jul 28. 1794576
    View PubMed
  87. Harikumar KG, Pinon DI, Miller LJ. Fluorescent indicators distributed throughout the pharmacophore of cholecystokinin provide insights into distinct modes of binding and activation of type A and B cholecystokinin receptors. J Biol Chem. 2006 Sep 15; 281(37):27072-80. Epub 2006 Jul 20. 1782345
    View PubMed
  88. Lisenbee CS, Miller LJ. Secretin receptor oligomers form intracellularly during maturation through receptor core domains. Biochemistry. 2006 Jul 11; 45(27):8216-26. 1770099
    View PubMed
  89. Dong M, Hosohata K, Pinon DI, Muthukumaraswamy N, Miller LJ. Differential spatial approximation between secretin and its receptor residues in active and inactive conformations demonstrated by photoaffinity labeling. Mol Endocrinol. 2006 Jul; 20(7):1688-98. Epub 2006 Mar 02. 1769884
    View PubMed
  90. Dong M, Pinon DI, Asmann YW, Miller LJ. Possible endogenous agonist mechanism for the activation of secretin family G protein-coupled receptors. Mol Pharmacol. 2006 Jul; 70(1):206-13. Epub 2006 Mar 10. 1769954
    View PubMed
  91. Dong M, Miller LJ. Use of photoaffinity labeling to understand the molecular basis of ligand binding to the secretin receptor. Ann N Y Acad Sci. 2006 Jul; 1070:248-64. 1782498
    View PubMed
  92. Dong M, Miller LJ. Molecular approximation between residue 10 of secretin and its receptor demonstrated by photoaffinity labeling. Ann N Y Acad Sci. 2006 Jul; 1070:243-7. 1782499
    View PubMed
  93. Matsuura B, Dong M, Naik S, Miller LJ, Onji M. Differential contributions of motilin receptor extracellular domains for peptide and non-peptidyl agonist binding and activity. J Biol Chem. 2006 May 5; 281(18):12390-6. Epub 2006 Mar 10. 1760878
    View PubMed
  94. Hayes GM, Carrigan PE, Beck AM, Miller LJ. Targeting the RNA splicing machinery as a novel treatment strategy for pancreatic carcinoma. Cancer Res. 2006 Apr 1; 66(7):3819-27. 1758074
    View PubMed
  95. Harikumar KG, Pinon DI, Miller LJ. Fluorescence characteristics of hydrophobic partial agonist probes of the cholecystokinin receptor. Biosci Rep. 2006 Apr; 26(2):89-100. 1775844
    View PubMed
  96. Takeshita E, Matsuura B, Dong M, Miller LJ, Matsui H, Onji M. Molecular characterization and distribution of motilin family receptors in the human gastrointestinal tract. J Gastroenterol. 2006 Mar; 41(3):223-30. 1760824
    View PubMed
  97. Hadac EM, Dawson ES, Darrow JW, Sugg EE, Lybrand TP, Miller LJ. Novel benzodiazepine photoaffinity probe stereoselectively labels a site deep within the membrane-spanning domain of the cholecystokinin receptor. J Med Chem. 2006 Feb 9; 49(3):850-63. 1752250
    View PubMed
  98. Harikumar KG, Hosohata K, Pinon DI, Miller LJ. Use of probes with fluorescence indicator distributed throughout the pharmacophore to examine the peptide agonist-binding environment of the family B G protein-coupled secretin receptor. J Biol Chem. 2006 Feb 3; 281(5):2543-50. Epub 2005 Nov 30. 1747095
    View PubMed
  99. Harikumar KG, Morfis MM, Lisenbee CS, Sexton PM, Miller LJ. Constitutive formation of oligomeric complexes between family B G protein-coupled vasoactive intestinal polypeptide and secretin receptors. Mol Pharmacol. 2006 Jan; 69(1):363-73. Epub 2005 Oct 21. 1744076
    View PubMed
  100. Korner M, Hayes GM, Rehmann R, Zimmermann A, Friess H, Miller LJ, Reubi JC. Secretin receptors in normal and diseased human pancreas - Marked reduction of receptor binding in ductal neoplasia. Am J Pathol. 2005 Oct; 167(4):959-68. 1732040
    View PubMed
  101. Pham V, Dong MQ, Wade JD, Miller LJ, Morton CJ, Ng H, Parker MW, Sexton PM. Insights into interactions between the alpha-helical region of the salmon calcitonin antagonists and the human calcitonin receptor using photoaffinity labeling. J Biol Chem. 2005 Aug 5; 280(31):28610-22. 1729856
    View PubMed
  102. Dong MQ, Pinon DI, Miller LJ. Insights into the structure and molecular basis of ligand docking to the G protein-coupled secretin receptor using charge-modified amino-terminal agonist probes. Molecular Endocrinology. 2005 Jul; 19(7):1821-36. 1720571
    View PubMed
  103. Dong M, Hadac EM, Pinon DI, Miller LJ. Differential spatial approximation between cholecystokinin residue 30 and receptor residues in active and inactive conformations. Mol Pharmacol. 2005 Jun; 67(6):1892-900. 1716407
    View PubMed
  104. Matsuura B, Dong M, Coulie B, Pinon DI, Miller LJ. Demonstration of a specific site of covalent labeling of the human motilin receptor using a biologically active photolabile motilin analog. Journal of Pharmacology & Experimental Therapeutics. 2005 Jun; 313(3):1101-8. 1716409
    View PubMed
  105. Harikumar KG, Miller LJ. Fluorescence resonance energy transfer analysis of the antagonist- and partial agonist-occupied states of the cholecystokinin receptor. J Biol Chem. 2005 May 13; 280(19):18631-5. Epub 2005 Mar 09. 1716412
    View PubMed
  106. Cheng ZJ, Harikumar KG, Ding WQ, Holicky EL, Miller LJ. Analysis of the cellular and molecular mechanisms of trophic action of a misspliced form of the type B cholecystokinin receptor present in colon and pancreatic cancer. Cancer Lett. 2005 May 10; 222(1):95-105. 1714671
    View PubMed
  107. Dong MQ, Liu GM, Pinon DI, Miller LJ. Differential docking of high-affinity peptide ligands to type A and B cholecystokinin receptors demonstrated by photoaffinity labeling. Biochemistry. 2005 May 3; 44(17):6693-700. 1708460
    View PubMed
  108. Lisenbee CS, Dong MQ, Miller LJ. Paired cysteine mutagenesis to establish the pattern of disulfide bonds in the functional intact secretin receptor. J Biol Chem. 2005 Apr 1; 280(13):12330-8. 1708138
    View PubMed
  109. Harikumar KG, Puri V, Singh RD, Hanada K, Pagano RE, Miller LJ. Differential effects of modification of membrane cholesterol and sphingolipids on the conformation, function, and trafficking of the G protein-coupled cholecystokinin receptor. J Biol Chem. 2005 Jan 21; 280(3):2176-85. Epub 2004 Nov 10. 1680878
    View PubMed
  110. Harikumar KG, Clain J, Pinon DI, Dong M, Miller LJ. Distinct molecular mechanisms for agonist peptide binding to types A and B cholecystokinin receptors demonstrated using fluorescence spectroscopy. J Biol Chem. 2005 Jan 14; 280(2):1044-50. Epub 2004 Nov 01. 1680789
    View PubMed
  111. Asmann YW, Dong MQ, Miller LJ. Functional characterization and purification of the secretin receptor expressed in baculovirus-infected insect cells. Regul Pept. 2004 Dec 15; 123(1-3):217-23. 1674013
    View PubMed
  112. Arlander SJH, Dong MQ, Ding XQ, Pinon DI, Miller LJ. Key differences in molecular complexes of the cholecystokinin receptor with structurally related peptide agonist, partial agonist, and antagonist. Mol Pharmacol. 2004 Sep; 66(3):545-52. 1662380
    View PubMed
  113. Dong MQ, Pinon DI, Cox RF, Miller LJ. Molecular approximation between a residue in the amino-terminal region of calcitonin and the third extracellular loop of the class B G protein-coupled calcitonin receptor. J Biol Chem. 2004 Jul 23; 279(30):31177-82. 1657314
    View PubMed
  114. Conti AM, Brimijoin S, Miller LJ, Windebank AJ. Suppression of neurite outgrowth by high-dose nerve growth factor is independent of functional p75NTR receptors. Neurobiol Dis. 2004 Feb; 15(1):106-14. 1519912
    View PubMed
  115. Dong MQ, Li ZJ, Pinon DI, Lybrand TP, Miller LJ. Spatial approximation between the amino terminus of a peptide agonist and the top of the sixth transmembrane segment of the secretin receptor. J Biol Chem. 2004 Jan 23; 279(4):2894-903. 1517960
    View PubMed
  116. Dong MQ, Pinon DI, Cox RF, Miller LJ. Importance of the amino terminus in secretin family G protein-coupled receptors - Intrinsic photoaffinity labeling establishes initial docking constraints for the calcitonin receptor. J Biol Chem. 2004 Jan 9; 279(2):1167-75. 1431727
    View PubMed
  117. Harikumar KG, Pinon DI, Wessels WS, Dawson ES, Lybrand TP, Prendergast FG, Miller LJ. Measurement of intermolecular distances for the natural agonist Peptide docked at the cholecystokinin receptor expressed in situ using fluorescence resonance energy transfer. Mol Pharmacol. 2004 Jan; 65(1):28-35. 1517875
    View PubMed
  118. Cheng ZJ, Harikumar KG, Holicky EL, Miller LJ. Heterodimerization of type A and B cholecystokinin receptors enhance signaling and promote cell growth. J Biol Chem. 2003 Dec 26; 278(52):52972-9. Epub 2003 Oct 08. 1431549
    View PubMed
  119. Dong MQ, Li ZJ, Zang MQ, Pinon DI, Lybrand TP, Miller LJ. Spatial approximation between two residues in the mid-region of secretin and the amino terminus of its receptor - Incorporation of seven sets of such constraints into a three-dimensional model of the agonist-bound secretin receptor. J Biol Chem. 2003 Nov 28; 278(48):48300-12. 1425130
    View PubMed
  120. Fernandez-Zapico ME, Mladek A, Ellenrieder V, Folch-Puy E, Miller L, Urrutia R. An mSin3A interaction domain links the transcriptional activity of KLF11 with its role in growth regulation. EMBO J. 2003 Sep 15; 22(18):4748-58. 1415041
    View PubMed
  121. Zang MW, Dong MQ, Pinon DI, Ding XQ, Hadac EM, Li ZJ, Lybrand TP, Miller LJ. Spatial approximation between a photolabile residue in position 13 of secretin and the amino terminus of the secretin receptor. Mol Pharmacol. 2003 May; 63(5):993-1001. 1340414
    View PubMed
  122. Mayo KE, Miller LJ, Bataille D, Dalle S, Goke B, Thorens B, Drucker DJ. International union of pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev. 2003 Mar; 55(1):167-94. 1318880
    View PubMed
  123. Ding XQ, Dolu V, Hadac EM, Schuetz M, Miller LJ. Disulfide bond structure and accessibility of cysteines in the ectodomain of the cholecystokinin receptor: Specific mono-reactive receptor constructs examine charge-sensitivity of loop regions. Receptors & Channels. 2003 Mar-Apr; 9(2):83-91. 1422385
    View PubMed
  124. Ding WQ, Dong M, Ninova D, Holicky EL, Stegall MD, Miller LJ. Forskolin suppresses insulin gene transcription in islet beta-cells through a protein kinase A-independent pathway. Cell Signal. 2003 Jan; 15(1):27-35. 1318033
    View PubMed
  125. Dawson ES, Henne RM, Miller LJ, Lybrand TP. Moleular models for cholecystokinin-A receptor. Pharmacology & Toxicology. 2002 Dec; 91(6):290-6. 1638866
    View PubMed
  126. Miller LJ, Lybrand TP. Molecular basis of agonist binding to the type A cholecystokinin receptor. Pharmacology & Toxicology. 2002 Dec; 91(6):282-5. 1317833
    View PubMed
  127. Harikumar KG, Miller LJ. Applications of fluorescence in the characterization of the ligand-binding domain and activation of the cholecystokinin receptor. Pharmacol Toxicol. 2002 Dec; 91(6):286-9. 1317834
    View PubMed
  128. Dong MQ, Pinon DI, Miller LJ. Development of a biologically active secretin analogue incorporating a radioiodinatable photolabile p-(4-hydroxybenzoyl)phenylalanine in position 10. Regul Pept. 2002 Nov 15; 109(1-3):181-7. 1644375
    View PubMed
  129. Dong MQ, Zang MW, Pinon DI, Li ZJ, Lybrand TP, Miller LJ. Interaction among four residues distributed through the secretin pharmacophore and a focused region of the secretin receptor amino terminus. Mol Endocrinol. 2002 Nov; 16(11):2490-501. 1644376
    View PubMed
  130. Chari ST, Yadav D, Smyrk TC, DiMagno EP, Miller LJ, Raimondo M, Clain JE, Norton IA, Pearson RK, Petersen BT, Wiersema MJ, Farnell MB, Sarr MG. Study of recurrence after surgical resection of intraductal papillary mucinous neoplasm of the pancreas. Gastroenterology. 2002 Nov; 123(5):1500-7. 1316819
    View PubMed
  131. Ding WQ, Cheng ZJ, McElhiney J, Kuntz SM, Miller LJ. Silencing of secretin receptor function by dimerization with a misspliced variant secretin receptor in ductal pancreatic adenocarcinoma. Cancer Res. 2002 Sep 15; 62(18):5223-9. 1316198
    View PubMed
  132. Harikumar KG, Pinon DI, Wessels WS, Prendergast FG, Miller LJ. Environment and mobility of a series of fluorescent reporters at the amino terminus of structurally related peptide agonists and antagonists bound to the cholecystokinin receptor. J Biol Chem. 2002 May 24; 277(21):18552-60. Epub 2002 Mar 13. 1315961
    View PubMed
  133. Ding XQ, Pinon DI, Furse KE, Lybrand TP, Miller LJ. Refinement of the conformation of a critical region of charge-charge interaction between cholecystokinin and its receptor. Mol Pharmacol. 2002 May; 61(5):1041-52. 1315597
    View PubMed
  134. Matsuura B, Dong MQ, Miller LJ. Differential determinants for peptide and non-peptidyl ligand binding to the motilin receptor - Critical role of second extracellular loop for peptide binding and action. J Biol Chem. 2002 Mar 22; 277(12):9834-9. 1315445
    View PubMed
  135. Ding WQ, Kuntz SM, Miller LJ. A misspliced form of the cholecystokinin-B/gastrin receptor in pancreatic carcinoma: Role of reduced cellular U2AF35 and a suboptimal 3 '-splicing site leading to retention of the fourth intron. Cancer Res. 2002 Feb 1; 62(3):947-52. 1008154
    View PubMed
  136. Ding WQ, Kuntz S, Bohmig M, Wiedenmann B, Miller LJ. Dominant negative action of an abnormal secretin receptor arising from mRNA missplicing in a gastrinoma. Gastroenterology. 2002 Feb; 122(2):500-11. 1008140
    View PubMed
  137. Dong MQ, Miller LJ. Molecular pharmacology of the secretin receptor. Receptors & Channels. 2002; 8(3-4 Special Issue SI):189-200. 1316189
    View PubMed
  138. Ding WQ, Dong M, Ninova D, Holicky EL, Stegall MD, Miller LJ. Forskolin surpresses insulin gene transcription in islet beta cells through a protein kinase A-independent pathway. Cellular Signaling. 2002; 15:27-35. 1316533
    View PubMed
  139. Ding WQ, Miller LJ. Signaling from novel splice variants of hormone receptors in cancer. Int J Gastrointest Cancer. 2002; 31(1-3):31-9. 1318462
    View PubMed
  140. Cheng ZJ, Miller LJ. Agonist-dependent dissociation of oligomeric complexes of G protein-coupled cholecystokinin receptors demonstrated in living cells using bioluminescence resonance energy transfer. J Biol Chem. 2001 Dec 21; 276(51):48040-7. Epub 2001 Oct 22 1007291
    View PubMed
  141. Shin DM, Luo X, Wilkie TM, Miller LJ, Peck AB, Humphreys-Beher MG, Muallem S. Polarized expression of G protein-coupled receptors and an all-or-none discharge of Ca2+ pools at initiation sites of [Ca2+]i waves in polarized exocrine cells. J Biol Chem. 2001 Nov 23; 276(47):44146-56. Epub 2001 Sep 11 1006948
    View PubMed
  142. Ding WQ, Holicky E, Miller LJ. Glucose and forskolin regulate IAPP gene expression through different signal transduction pathways. Am J Physiol Endocrinol Metab. 2001 Nov; 281(5):E938-45. 1006421
    View PubMed
  143. Coulie B, Matsuura B, Dong M, Hadac EM, Pinon DI, Feighner SD, Howard AD, Miller LJ. Identification of peptide ligand-binding domains within the human motilin receptor using photoaffinity labeling. J Biol Chem. 2001 Sep 21; 276(38):35518-22. Epub 2001 Jul 18 1004103
    View PubMed
  144. Roettger BF, Hellen EH, Burghardt TP, Miller LJ. Multiple ligand and cell-dependent states of lateral mobility of plasmalemmal G protein-coupled cholecystokinin receptors. Journal of Fluorescence. 2001 Sep; 11(3):237-46. 1006815
  145. Nardone G, Holicky EL, Uhl JR, Sabatino L, Staibano S, Rocco A, Colantuoni V, Manzo BA, Romano M, Budillon G, Cockerill FR, Miller LJ. In vivo and in vitro studies of cytosolic phospholipase A2 expression in Helicobacter pylori infection. Infect Immun. 2001 Sep; 69(9):5857-63. 1006108
    View PubMed
  146. Ding XQ, Ding WQ, Miller LJ. Receptor biology and signal transduction. Curr Opin Gastroenterol. 2001 Sep; 17(5):410-5. 1006089
    View PubMed
  147. Chari ST, Klee GG, Miller LJ, Raimondo M, DiMagno EP. Islet amyloid polypeptide is not a satisfactory marker for detecting pancreatic cancer. Gastroenterology. 2001 Sep; 121(3):640-5. 1014770
    View PubMed
  148. Ding XQ, Miller LJ. Characterization of the type A cholecystokinin receptor hormone-binding domain: use of contrasting and complementary methodologies. Peptides. 2001 Aug; 22(8):1223-8. 1005590
    View PubMed
  149. Holicky EL, Hadac EM, Ding XQ, Miller LJ. Molecular characterization and organ distribution of type A and B cholecystokinin receptors in cynomolgus monkey. Am J Physiol Gastrointest Liver Physiol. 2001 Aug; 281(2):G507-14. 1005627
    View PubMed
  150. Jiang SW, Dong M, Trujillo MA, Miller LJ, Eberhardt NL. DNA binding of TEA/ATTS domain factors is regulated by protein kinase C phosphorylation in human choriocarcinoma cells. J Biol Chem. 2001 Jun 29; 276(26):23464-70. Epub 2001 Apr 19. 1005302
    View PubMed
  151. Ding XQ, Dolu V, Hadac EM, Holicky EL, Pinon DI, Lybrand TP, Miller LJ. Refinement of the structure of the ligand-occupied cholecystokinin receptor using a photolabile amino-terminal probe. J Biol Chem. 2001 Feb 9; 276(6):4236-44. Epub 2000 Oct 24 1005133
    View PubMed
  152. Tietz PS, Hadac EM, Miller LJ, LaRusso NF. Upregulation of secretin receptors on cholangiocytes after bile duct ligation. Regul Pept. 2001 Feb 2; 97(1):1-6. 1003547
    View PubMed
  153. Miller LJ, Ding XQ. Insights into the molecular basis of ligand binding by the cholecystokinin receptor. Pancreatology. 2001; 1(4):336-42. 1007233
    View PubMed
  154. Ding XQ, Rao RV, Kuntz SM, Holicky EL, Miller LJ. Impaired resensitization and recycling of the cholecystokinin receptor by co-expression of its second intracellular loop. Mol Pharmacol. 2000 Dec; 58(6):1424-33. 140471
    View PubMed
  155. Rao RV, Holicky EL, Kuntz SM, Miller LJ. CCK receptor phosphorylation exposes regulatory domains affecting phosphorylation and receptor trafficking. Am J Physiol Cell Physiol. 2000 Dec; 279(6):C1986-92. 140455
    View PubMed
  156. Miller LJ, Coulie B. Characterization of the motilin receptor, a member of a new receptor family. Digestive & Liver Disease. 2000 Dec; 32(Suppl 3):S223-4. 1013867
  157. Asmann YW, Dong M, Ganguli S, Hadac EM, Miller LJ. Structural insights into the amino-terminus of the secretin receptor: I. Status of cysteine and cystine residues. Mol Pharmacol. 2000 Nov; 58(5):911-9. 139450
    View PubMed
  158. Park CG, Ganguli SC, Pinon DI, Hadac EM, Miller LJ. Cross-chimeric analysis of selectivity of secretin and VPAC(1) receptor activation. Journal of Pharmacology & Experimental Therapeutics. 2000 Nov; 295(2):682-8. 139555
    View PubMed
  159. Dong M, Asmann YW, Zang M, Pinon DI, Miller LJ. Identification of two pairs of spatially approximated residues within the carboxyl terminus of secretin and its receptor. J Biol Chem. 2000 Aug 25; 275(34):26032-9. 136937
    View PubMed
  160. Dong M, Wang Y, Miller LJ. Dual contacts between peptide agonist ligands and the secretin receptor directly established by photoaffinity labeling. Ann N Y Acad Sci. 2000; 921:381-6. 1013870
    View PubMed
  161. Pang RT, Ng SS, Cheng CH, Holtmann MH, Miller LJ, Chow BK. Role of N-linked glycosylation on the function and expression of the human secretin receptor. Endocrinology. 1999 Nov; 140(11):5102-11. 123365
    View PubMed
  162. Sternini C, Wong H, Pham T, De Giorgio R, Miller LJ, Kuntz SM, Reeve JR, Walsh JH, Raybould HE. Expression of cholecystokinin A receptors in neurons innervating the rat stomach and intestine. Gastroenterology. 1999 Nov; 117(5):1136-46. 123518
    View PubMed
  163. Dong M, Wang Y, Hadac EM, Pinon DI, Holicky E, Miller LJ. Identification of an interaction between residue 6 of the natural peptide ligand and a distinct residue within the amino-terminal tail of the secretin receptor. J Biol Chem. 1999 Jul 2; 274(27):19161-7. 117629
    View PubMed
  164. Hadac EM, Ji Z, Pinon DI, Henne RM, Lybrand TP, Miller LJ. A peptide agonist acts by occupation of a monomeric G protein-coupled receptor: dual sites of covalent attachment to domains near TM1 and TM7 of the same molecule make biologically significant domain-swapped dimerization unlikely. J Med Chem. 1999 Jun 17; 42(12):2105-11. 117128
    View PubMed
  165. Miller LJ. Advances in molecular genetics for the pancreatologist. Curr Gastroenterol Rep. 1999 Apr; 1(2):132-3. 1424871
    View PubMed
  166. Roettger BF, Pinon DI, Burghardt TP, Miller LJ. Regulation of lateral mobility and cellular trafficking of the CCK receptor by a partial agonist. Am J Physiol. 1999 Mar; 276(3 Pt 1):C539-47. 109795
    View PubMed
  167. Dong M, Ding XQ, Pinon DI, Hadac EM, Oda RP, Landers JP, Miller LJ. Structurally related peptide agonist, partial agonist, and antagonist occupy a similar binding pocket within the cholecystokinin receptor. Rapid analysis using fluorescent photoaffinity labeling probes and capillary electrophoresis. J Biol Chem. 1999 Feb 19; 274(8):4778-85. 1314516
    View PubMed
  168. Dong M, Wang Y, Pinon DI, Hadac EM, Miller LJ. Demonstration of a direct interaction between residue 22 in the carboxyl-terminal half of secretin and the amino-terminal tail of the secretin receptor using photoaffinity labeling. J Biol Chem. 1999 Jan 8; 274(2):903-9. 109061
    View PubMed
  169. Ulrich CD 2nd, Wood P, Hadac EM, Kopras E, Whitcomb DC, Miller LJ. Cellular distribution of secretin receptor expression in rat pancreas. Am J Physiol. 1998 Dec; 275(6 Pt 1):G1437-44. 108993
    View PubMed
  170. Darrow JW, Hadac EM, Miller LJ, Sugg EE. Structurally similar small molecule photoaffinity CCK-a agonists and antagonists as novel tools for directly probing 7TM receptor-ligand interactions. Bioorg Med Chem Lett. 1998 Nov 17; 8(22):3127-32. 109070
    View PubMed
  171. Urrutia R, Miller LJ. Novel membrane-to-nucleus pathways in the regulation of pancreatic acinar cell function. Curr Opin Gastroenterol. 1998 Sep; 14(5):369-375. 107886
  172. Ganguli SC, Park CG, Holtmann MH, Hadac EM, Kenakin TP, Miller LJ. Protean effects of a natural peptide agonist of the G protein-coupled secretin receptor demonstrated by receptor mutagenesis. Journal of Pharmacology & Experimental Therapeutics. 1998 Aug; 286(2):593-8. 107481
    View PubMed
  173. Go WY, Holicky EL, Hadac EM, Rao RV, Miller LJ. Identification of a domain in the carboxy terminus of CCK receptor that affects its intracellular trafficking. Am J Physiol Gastrointest Liver Physiol. 1998 Jul; 275(1):G 56-G 62. 1019329
  174. Hadac EM, Pinon DI, Ji Z, Holicky EL, Henne RM, Lybrand TP, Miller LJ. Direct identification of a second distinct site of contact between cholecystokinin and its receptor. J Biol Chem. 1998 May 22; 273(21):12988-93. 105431
    View PubMed
  175. Marlowe KJ, Farshori P, Torgerson RR, Anderson KL, Miller LJ, McNiven MA. Changes in kinesin distribution and phosphorylation occur during regulated secretion in pancreatic acinar cells. Eur J Cell Biol. 1998 Feb; 75(2):140-52. 104167
    View PubMed
  176. Smeets RL, Rao RV, van Emst-de Vries SE, De Pont JJ, Miller LJ, Willems PH. Reduced cholecystokinin receptor phosphorylation and restored signalling in protein kinase C down-regulated rat pancreatic acinar cells. Pflugers Arch. 1998 Feb; 435(3):422-8. 102888
    View PubMed
  177. Ulrich CD 2nd, Holtmann M, Miller LJ. Secretin and vasoactive intestinal peptide receptors: members of a unique family of G protein-coupled receptors. Gastroenterology. 1998 Feb; 114(2):382-97. 102908
    View PubMed
  178. Urrutia R, Miller LJ, DiMagno EP. 1996 Comfort Symposium on Pancreatic Carcinogenesis. Pancreas. 1998 Jan; 16(1):1-5. 102660
    View PubMed
  179. Go W, Holicky EL, Hadac EM, Rao RV, Miller LJ. Effects of mutagenesis and truncation of the carboxyl-terminus of the cholecystokinin receptor on ligand binding, signaling, and receptor internalization. Am J Physiol. 1998; 275:G56-62. 150497
    View PubMed
  180. Urrutia R, Miller LJ, DiMagno EP. 1999 Cell signaling and transcription regulation in acinar epithelial cells. Curr Opin Gastroenterol. 1998; 16(1):1-5. 147613
  181. Ji Z, Hadac EM, Henne RM, Patel SA, Lybrand TP, Miller LJ. Direct identification of a distinct site of interaction between the carboxyl-terminal residue of cholecystokinin and the type A cholecystokinin receptor using photoaffinity labeling. J Biol Chem. 1997 Sep 26; 272(39):24393-401. 100191
    View PubMed
  182. Dong MQ, Oda RP, Strausbauch MA, Wettstein PJ, Landers JP, Miller LJ. Hydrophobic peptide mapping of clinically relevant heptahelical membrane proteins by capillary electrophoresis. Electrophoresis. 1997 Sep; 18(10):1767-1774. 100768
    View PubMed
  183. Ghanekar D, Hadac EM, Holicky EL, Miller LJ. Differences in partial agonist action at cholecystokinin receptors of mouse and rat are dependent on parameters extrinsic to receptor structure: molecular cloning, expression and functional characterization of the mouse type A cholecystokinin receptor. Journal of Pharmacology & Experimental Therapeutics. 1997 Sep; 282(3):1206-12. 100128
    View PubMed
  184. Rao RV, Hadac EM, Roettger BF, Miller LJ. Cholecystokinin-induced desensitization, receptor phosphorylation, and internalization in the CHP212 neuroblastoma cell line. J Neurochem. 1997 Jun; 68(6):2356-62. 102490
    View PubMed
  185. Go WY, Roettger BF, Holicky EL, Hadac EM, Miller LJ. Quantitative dynamic multicompartmental analysis of cholecystokinin receptor movement in a living cell using dual fluorophores and reconstruction of confocal images. Anal Biochem. 1997 May 1; 247(2):210-5. 102493
    View PubMed
  186. Roettger BF, Ghanekar D, Rao R, Toledo C, Yingling J, Pinon D, Miller LJ. Antagonist-stimulated internalization of the G protein-coupled cholecystokinin receptor. Mol Pharmacol. 1997 Mar; 51(3):357-62. 101954
    View PubMed
  187. Detoledo CF, Roettger BF, Moryswortmann C, Schmidt WE, Miller LJ. Cellular handling of unoccupied and agonist-stimulated cholecystokinin receptor determined by immunolocalization. Am J Physiol Gastrointest Liver Physiol. 1997 Mar; 272(3):G 488-G 497. 101981
  188. Rao RV, Roettger BF, Hadac EM, Miller LJ. Roles of cholecystokinin receptor phosphorylation in agonist-stimulated desensitization of pancreatic acinar cells and receptor-bearing Chinese hamster ovary cholecystokinin receptor cells. Mol Pharmacol. 1997 Feb; 51(2):185-92. 101745
    View PubMed
  189. Alpini G, Ulrich C, Roberts S, Phillips JO, Ueno Y, Podila PV, Colegio O, Lesage GD, Miller LJ, LaRusso NF. Molecular and functional heterogeneity of cholangiocytes from rat liver after bile duct ligation. Am J Physiol Gastrointest Liver Physiol. 1997 Feb; 272(2):G 289-G 297. 101806
  190. Holtmann MH, Hadac EM, Ulrich CD, Miller LJ. Molecular basis and species specificity of high affinity binding of vasoactive intestinal polypeptide by the rat secretin receptor. Journal of Pharmacology & Experimental Therapeutics. 1996 Nov; 279(2):555-60. 98063
    View PubMed
  191. Holtmann MH, Roettger BF, Pinon DI, Miller LJ. Role of receptor phosphorylation in desensitization and internalization of the secretin receptor. J Biol Chem. 1996 Sep 20; 271(38):23566-71. 97778
    View PubMed
  192. Ji Z, Pinon DI, Miller LJ. Development of magnetic beads for rapid and efficient metal-chelate affinity purifications. Anal Biochem. 1996 Sep 5; 240(2):197-201. 97797
    View PubMed
  193. Hadac EM, Ghanekar DV, Holicky EL, Pinon DI, Dougherty RW, Miller LJ. Relationship between native and recombinant cholecystokinin receptors: role of differential glycosylation. Pancreas. 1996 Aug; 13(2):130-9. 97109
    View PubMed
  194. Holtmann MH, Ganguli S, Hadac EM, Dolu V, Miller LJ. Multiple extracellular loop domains contribute critical determinants for agonist binding and activation of the secretin receptor. J Biol Chem. 1996 Jun 21; 271(25):14944-9. 95288
    View PubMed
  195. Ozcelebi F, Rao RV, Holicky E, Madden BJ, McCormick DJ, Miller LJ. Phosphorylation of cholecystokinin receptors expressed on Chinese hamster ovary cells. Similarities and differences relative to native pancreatic acinar cell receptors. J Biol Chem. 1996 Feb 16; 271(7):3750-5. 95554
    View PubMed
  196. Aquino CJ, Armour DR, Berman JM, Birkemo LS, Carr RA, Croom DK, Dezube M, Dougherty RW Jr, Ervin GN, Grizzle MK, Head JE, Hirst GC, James MK, Johnson MF, Miller LJ, Queen KL, Rimele TJ, Smith DN, Sugg EE. Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity. 1. Optimization of the agonist "trigger". J Med Chem. 1996 Jan 19; 39(2):562-9. 95259
    View PubMed
  197. Katz M, Carangelo R, Miller LJ, Gorelick F. Effect of ethanol on cholecystokinin-stimulated zymogen conversion in pancreatic acinar cells. Am J Physiol Gastrointest Liver Physiol. 1996 Jan; 33(1):G 171-G 175. 95630
  198. Belov L, Akhter J, Meher-Homji V, Nicholson S, Miller LJ, Morris DL. Monoclonal antibody 2C1 does not recognise the CCK-B (gastrin) receptor. Surg Res Commun. 1996; 18:183-95. 1424826
  199. Nardone G, Ferber IA, Miller LJ. The integrity of the cholecystokinin receptor gene in gallbladder disease and obesity. Hepatology. 1995 Dec; 22(6):1751-3. 91100
    View PubMed
  200. Tietz PS, Holman RT, Miller LJ, LaRusso NF. Isolation and characterization of rat cholangiocyte vesicles enriched in apical or basolateral plasma membrane domains. Biochemistry. 1995 Nov 28; 34(47):15436-43. 91180
    View PubMed
  201. Ozcelebi F, Holtmann MH, Rentsch RU, Rao R, Miller LJ. Agonist-stimulated phosphorylation of the carboxyl-terminal tail of the secretin receptor. Mol Pharmacol. 1995 Nov; 48(5):818-24. 91197
    View PubMed
  202. Miller LJ, Holicky EL, Ulrich CD, Wieben ED. Abnormal processing of the human cholecystokinin receptor gene in association with gallstones and obesity. Gastroenterology. 1995 Oct; 109(4):1375-80. 93809
    View PubMed
  203. Roettger BF, Rentsch RU, Hadac EM, Hellen EH, Burghardt TP, Miller LJ. Insulation of a G protein-coupled receptor on the plasmalemmal surface of the pancreatic acinar cell. J Cell Biol. 1995 Aug; 130(3):579-90. 93160
    View PubMed
  204. Holtmann MH, Hadac EM, Miller LJ. Critical contributions of amino-terminal extracellular domains in agonist binding and activation of secretin and vasoactive intestinal polypeptide receptors. Studies of chimeric receptors. J Biol Chem. 1995 Jun 16; 270(24):14394-8. 93029
    View PubMed
  205. Roettger BF, Rentsch RU, Pinon D, Holicky E, Hadac E, Larkin JM, Miller LJ. Dual pathways of internalization of the cholecystokinin receptor. J Cell Biol. 1995 Mar; 128(6):1029-41. 92455
    View PubMed
  206. Ozcelebi F, Miller LJ. Phosphopeptide mapping of cholecystokinin receptors on agonist-stimulated native pancreatic acinar cells. J Biol Chem. 1995 Feb 17; 270(7):3435-41. 91892
    View PubMed
  207. Sugg EE, Kimery MJ, Ding JM, Kenakin DC, Miller LJ, Queen KL, Rimele TJ. CCK-A receptor selective antagonists derived from the CCK-A receptor selective tetrapeptide agonist Boc-Trp-Lys(Tac)-Asp-MePhe-NH2 (A- 71623). J Med Chem. 1995 Jan 6; 38(1):207-11. 91751
    View PubMed
  208. Lutz MP, Pinon DI, Miller LJ. A nonradioactive fluorescent gel-shift assay for the analysis of protein phosphatase and kinase activities toward protein-specific peptide substrates. Anal Biochem. 1994 Aug 1; 220(2):268-74. 88991
    View PubMed
  209. Miller LJ, Hadac EM, Powers SP. Preparation of radiolabeled photolabile probes of high specific radioactivity for affinity labeling. Anal Biochem. 1994 Aug 1; 220(2):434-5. 88992
    View PubMed
  210. Gaisano HY, Miller LJ, Foskett JK. Suppression of Ca2+ oscillations induced by cholecystokinin (CCK) and its analog OPE in rat pancreatic acinar cells by low-level protein kinase C activation without transition of the CCK receptor from a high- to low-affinity state. Pflugers Arch. 1994 Jul; 427(5-6):455-62. 88830
    View PubMed
  211. Lutz MP, Pinon DI, Miller LJ. Characterization of protein serine/threonine phosphatases in rat pancreas and development of an endogenous substrate-specific phosphatase assay. Pancreas. 1994 Jul; 9(4):418-24. 88412
    View PubMed
  212. Gaisano HY, Miller LJ. Low concentrations of protein kinase C-activating agonists suppress cholecystokinin-OPE-evoked Ca2+ mobilization in rat pancreatic acini. Pancreas. 1994 Jul; 9(4):450-3. 88413
    View PubMed
  213. Alpini G, Ulrich CD 2nd, Phillips JO, Pham LD, Miller LJ, LaRusso NF. Upregulation of secretin receptor gene expression in rat cholangiocytes after bile duct ligation. Am J Physiol. 1994 May; 266(5 Pt 1):G922-8. 88377
    View PubMed
  214. Zhu Z, Lutz M, Gates LK, Miller LJ. Mechanisms of heterologous agonist-stimulated phosphorylation of cholecystokinin receptor. Am J Physiol. 1994 Apr; 266(4 Pt 1):C904-10. 89149
    View PubMed
  215. Ulrich CD 2nd, Pinon DI, Hadac EM, Holicky EL, Chang-Miller A, Gates LK, Miller LJ. Intrinsic photoaffinity labeling of native and recombinant rat pancreatic secretin receptors. Gastroenterology. 1993 Nov; 105(5):1534-43. 84640
    View PubMed
  216. Ulrich CD, Ferber I, Holicky E, Hadac E, Buell G, Miller LJ. Molecular cloning and functional expression of the human gallbladder cholecystokinin A receptor. Biochem Biophys Res Commun. 1993 May 28; 193(1):204-11. 85797
    View PubMed
  217. Lutz MP, Sutor SL, Abraham RT, Miller LJ. A role for cholecystokinin-stimulated protein tyrosine phosphorylation in regulated secretion by the pancreatic acinar cell. J Biol Chem. 1993 May 25; 268(15):11119-24. 83715
    View PubMed
  218. Gates LK, Ulrich CD, Miller LJ. Multiple kinases phosphorylate the pancreatic cholecystokinin receptor in an agonist-dependent manner. Am J Physiol. 1993 May; 264(5 Pt 1):G840-7. 83718
    View PubMed
  219. Marino CR, Leach SD, Schaefer JF, Miller LJ, Gorelick FS. Characterization of cAMP-dependent protein kinase activation by CCK in rat pancreas. FEBS Lett. 1993 Jan 18; 316(1):48-52. 85796
    View PubMed
  220. Lutz MP, Pinon DI, Gates LK, Shenolikar S, Miller LJ. Control of cholecystokinin receptor dephosphorylation in pancreatic acinar cells. J Biol Chem. 1993; 268:12136-12142. 85798
    View PubMed
  221. Lutz MP, Miller LJ. Cholecystokinin receptors: radioligand binding and affinity labeling. Methods in Neurosciences. 1993; 11:170-185. 85799
  222. Miller LJ. Cell-surface receptors and pancreatic acinar cell physiology. Curr Opin Gastroenterol. 1993; 9:732-739. 84184
  223. Miller LJ. The biochemical characterization of the native pancreatic cholecystokinin receptor using affinity labeling approaches. Yale J Biol Med. 1992 Sep-Oct; 65(5):441-8; discussion 465-9. 81437
    View PubMed
  224. Farley DR, van Heerden JA, Grant CS, Miller LJ, Ilstrup DM. The Zollinger-Ellison syndrome. A collective surgical experience. Ann Surg. 1992 Jun; 215(6):561-9; discussion 569-70. 80322
    View PubMed
  225. Kopin AS, Lee YM, McBride EW, Miller LJ, Lu M, Lin HY, Kolakowski LF Jr, Beinborn M. Expression cloning and characterization of the canine parietal cell gastrin receptor. Proc Natl Acad Sci U S A. 1992 Apr 15; 89(8):3605-9. 81676
    View PubMed
  226. Miller LJ, Hadac EM, Gates LK, Gaisano HY. Binding of a phenethyl ester analogue of cholecystokinin to the solubilized pancreatic cholecystokinin receptor: use in ligand-affinity chromatography. Biochem Biophys Res Commun. 1992 Mar 16; 183(2):396-404. 79601
    View PubMed
  227. Gaisano HY, Miller LJ. Complex role of protein kinase C mediating the supramaximal inhibition of pancreatic secretion observed with cholecystokinin. Biochem Biophys Res Commun. 1992; 187:498-506. 81677
    View PubMed
  228. Miller LJ. Pancreatic acinar cell physiology and function. Curr Opin Gastroenterol. 1992; 8:801-807. 81679
  229. Farley DR, Van Heerden JA, Grant CS, Miller LJ, Ilstrup DM. The Zollinger-Ellison syndrome. Trans South Surg Assoc. 1991 Dec; 103:165-174. 1038137
  230. Kamath PS, Gaisano HY, Phillips SF, Miller LJ, Charboneau JW, Brown ML, Zinsmeister AR. Abnormal gallbladder motility in irritable bowel syndrome: evidence for target-organ defect. Am J Physiol. 1991 Jun; 260(6 Pt 1):G815-9. 76752
    View PubMed
  231. Klueppelberg UG, Gates LK, Gorelick FS, Miller LJ. Agonist-regulated phosphorylation of the pancreatic cholecystokinin receptor. J Biol Chem. 1991 Feb 5; 266(4):2403-8. 75900
    View PubMed
  232. Otterness DM, Powers SP, Miller LJ, Weinshilboum RM. 3'-phosphoadenosine-5'-phosphosulfate: photoaffinity ligand for sulfotransferase enzymes. Mol Pharmacol. 1991 Jan; 39(1):34-41. 78389
    View PubMed
  233. Lennon VA, Sas DF, Busk MF, Scheithauer B, Malagelada JR, Camilleri M, Miller LJ. Enteric neuronal autoantibodies in pseudoobstruction with small-cell lung carcinoma. Gastroenterology. 1991 Jan; 100(1):137-42. 78269
    View PubMed
  234. Powers SP, Foo I, Pinon D, Klueppelberg UG, Hedstrom JF, Miller LJ. Use of photoaffinity probes containing poly(ethylene glycol) spacers for topographical mapping of the cholecystokinin receptor complex. Biochemistry. 1991; 30:676-682. 78390
    View PubMed
  235. Molero X, Miller LJ. The gallbladder cholecystokinin receptor exists in two guamime nucleotide-binding protein-regulated affinity states. Mol Pharmacol. 1991; 39:150-156. 78391
    View PubMed
  236. Klueppelberg UG, Molero X, Barrett RW, Miller LJ. Biochemical characterization of the cholecystokinin receptor on CHP212 human neuroblastoma cells. Mol Pharmacol. 1990 Aug; 38(2):159-63. 74902
    View PubMed
  237. Tanaka M, Sarr MG, Miller LJ, Malagelada JR. Changes in tone of canine gallbladder measured by an electronic pneumatic barostat. Am J Physiol. 1990 Aug; 259(2 Pt 1):G314-20. 73279
    View PubMed
  238. Kost LJ, Gores GJ, Sayles JM, Miller LJ, Lemasters JJ, Herman B, LaRusso NF. Lack of metabolic effects of cholecystokinin on hepatocytes. Hepatology. 1990 Aug; 12(2):301-5. 73302
    View PubMed
  239. Hunter EB, Powers SP, Kost LJ, Pinon DI, Miller LJ, LaRusso NF. Physicochemical determinants in hepatic extraction of small peptides. Hepatology. 1990 Jul; 12(1):76-82. 73130
    View PubMed
  240. Schjoldager B, Molero X, Miller LJ. Gallbladder CCK receptors: species differences in glycosylation of similar protein cores. Regul Pept. 1990 May 21; 28(3):265-72. 74901
    View PubMed
  241. Talley NJ, Phillips SF, Haddad A, Miller LJ, Twomey C, Zinsmeister AR, MacCarty RL, Ciociola A. GR 38032F (ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man. Dig Dis Sci. 1990 Apr; 35(4):477-80. 72425
    View PubMed
  242. Klueppelberg UG, Powers SP, Miller LJ. The efficiency of covalent labeling of the pancreatic cholecystokinin receptor using a battery of cross-linkable and photolabile probes. Receptor. 1990; 1:1-11. 74900
    View PubMed
  243. Otterness DM, Powers SP, Miller LJ, Weinshilboum RM. Human liver thermostable phenol sulfotransferase: photoaffinity labeling with 2-iodo-4-azidophenol. Mol Pharmacol. 1989 Dec; 36(6):856-65. 70418
    View PubMed
  244. Duong LT, Hadac EM, Miller LJ, Vlasuk GP. Purification and characterization of the rat pancreatic cholecystokinin receptor. J Biol Chem. 1989 Oct 25; 264(30):17990-6. 70050
    View PubMed
  245. Klueppelberg UG, Powers SP, Miller LJ. Protease peptide mapping of affinity-labeled rat pancreatic cholecystokinin-binding proteins. Biochemistry. 1989 Aug 22; 28(17):7124-9. 69660
    View PubMed
  246. Gores GJ, Kost LJ, Miller LJ, LaRusso NF. Processing of cholecystokinin by isolated liver cells. Am J Physiol. 1989 Aug; 257(2 Pt 1):G242-8. 69664
    View PubMed
  247. Sas DF, Lundy JK, Miller LJ. Culture of human neoplastic gastrointestinal smooth muscle cells. In Vitro Cellular & Developmental Biology. 1989 Aug; 25(8):730-6. 69709
    View PubMed
  248. Pearson RK, Hadac EM, Miller LJ. Structural analysis of a distinct subtype of CCK receptor on human gastric smooth muscle tumors. Am J Physiol. 1989 Jun; 256(6 Pt 1):G1005-10. 71481
    View PubMed
  249. Klueppelberg UG, Gaisano HY, Powers SP, Miller LJ. Use of a nitrotryptophan-containing peptide for photoaffinity labeling the pancreatic cholecystokinin receptor. Biochemistry. 1989 Apr 18; 28(8):3463-8. 71207
    View PubMed
  250. Schjoldager B, Molero X, Miller LJ. Functional and biochemical characterization of the human gallbladder muscularis cholecystokinin receptor. Gastroenterology. 1989 Apr; 96(4):1119-25. 68821
    View PubMed
  251. Gaisano HY, Klueppelberg UG, Pinon DI, Pfenning MA, Powers SP, Miller LJ. Novel tool for the study of cholecystokinin-stimulated pancreatic enzyme secretion. J Clin Invest. 1989 Jan; 83(1):321-5. 71206
    View PubMed
  252. Talley NJ, Phillips SF, Haddad A, Miller LJ, Twomey C, Zinsmeister AR, Ciociola A. Effect of a selective 5HT3 antagonist (GR-38032F) on small intestinal transit and release of gastrointestinal peptides. Dig Dis Sci. 1989; 34:1511-1515. 71208
    View PubMed
  253. Schjoldager B, Powers SP, Miller LJ. Affinity labeling the bovine gallbladder cholecystokinin receptor using a battery of probes. Am J Physiol. 1988 Nov; 255(5 Pt 1):G579-86. 66807
    View PubMed
  254. Sas D, Miller LJ. Culture behavior of healthy bovine gallbladder muscularis smooth muscle cells. Am J Physiol. 1988 Nov; 255(5 Pt 1):G653-9. 67875
    View PubMed
  255. Kellow JE, Phillips SF, Miller LJ, Zinsmeister AR. Dysmotility of the small intestine in irritable bowel syndrome. Gut. 1988 Sep; 29(9):1236-43. 66188
    View PubMed
  256. Powers SP, Pinon DI, Miller LJ. Use of N,O-bis-Fmoc-D-Tyr-ONSu for introduction of an oxidative iodination site into cholecystokinin family peptides. International Journal of Peptide & Protein Research. 1988 May; 31(5):429-34. 67873
    View PubMed
  257. Schjoldager B, Shaw MJ, Powers SP, Schmalz PF, Szurszewski J, Miller LJ. Bovine gallbladder muscularis: source of a myogenic receptor for cholecystokinin. Am J Physiol. 1988 Mar; 254(3 Pt 1):G294-9. 1313329
    View PubMed
  258. Powers SP, Fourmy D, Gaisano H, Miller LJ. Intrinsic photoaffinity-labeling probes for cholecystokinin (CCK)-gastrin family receptors. D-Tyr-Gly(Nle28,31,pN02-Phe33) CCK-26-33. J Biol Chem. 1988; 263:5295-5300. 67872
    View PubMed
  259. Miller LJ, Powers SP. Biochemical characterization of the pancreatic cholecystokinin receptor: a possible marker of cell differentiation and development. Scand J Gastroenterol Suppl. 1988; 151:104-7. 67876
    View PubMed
  260. Kellow JE, Miller LJ, Phillips SF, Zinsmeister AR, Charboneau JW. Altered sensitivity of the gallbladder to cholecystokinin octapeptide in irritable bowel syndrome. Am J Physiol. 1987 Nov; 253(5 Pt 1):G650-5. 63295
    View PubMed
  261. Shaw MJ, Hadac EM, Miller LJ. Preparation of enriched plasma membranes from bovine gallbladder muscularis for characterization of cholecystokinin receptors. J Biol Chem. 1987 Oct 15; 262(29):14313-8. 64182
    View PubMed
  262. Pearson RK, Miller LJ, Hadac EM, Powers SP. Analysis of the carbohydrate composition of the pancreatic plasmalemmal glycoprotein affinity labeled by short probes for the cholecystokinin receptor. J Biol Chem. 1987 Oct 5; 262(28):13850-6. 64344
    View PubMed
  263. Pearson RK, Powers SP, Hadac EM, Gaisano H, Miller LJ. Establishment of a new short, protease-resistant, affinity labeling reagent for the cholecystokinin receptor. Biochem Biophys Res Commun. 1987 Aug 31; 147(1):346-53. 64345
    View PubMed
  264. Kellow JE, Miller LJ, Phillips SF, Haddad AC, Zinsmeister AR, Charboneau JW. Sensitivities of human jejunum, ileum, proximal colon, and gallbladder to cholecystokinin octapeptide. Am J Physiol. 1987 Mar; 252(3 Pt 1):G345-56. 61404
    View PubMed
  265. Pearson RK, Miller LJ. Affinity labeling of a novel cholecystokinin-binding protein in rat pancreatic plasmalemma using new short probes for the receptor. J Biol Chem. 1987 Jan 15; 262(2):869-76. 64348
    View PubMed
  266. Pearson RK, Miller LJ, Powers SP, Hadac EM. Biochemical characterization of the pancreatic cholecystokinin receptor using monofunctional photoactivatable probes. Pancreas. 1987; 2(1):79-84. 64347
    View PubMed
  267. van Heerden JA, Smith SL, Miller LJ. Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type I. Surgery. 1986 Dec; 100(6):971-7. 59407
    View PubMed
  268. Pearson RK, Hadac EM, Miller LJ. Preparation and characterization of a new cholecystokinin receptor probe that can be oxidatively radioiodinated. Gastroenterology. 1986 Jun; 90(6):1985-91. 58511
    View PubMed
  269. Miller LJ, Bouska JB, Go VL. Extraction of cholecystokinin peptides from biological fluids using octadecylsilane-packed cartridges. J Chromatogr. 1986 May 28; 378(1):77-84. 60513
    View PubMed
  270. Gores GJ, LaRusso NF, Miller LJ. Hepatic processing of cholecystokinin peptides. I. Structural specificity and mechanism of hepatic extraction. Am J Physiol. 1986 Mar; 250(3 Pt 1):G344-9. 57893
    View PubMed
  271. Gores GJ, Miller LJ, LaRusso NF. Hepatic processing of cholecystokinin peptides. II. Cellular metabolism, transport, and biliary excretion. Am J Physiol. 1986 Mar; 250(3 Pt 1):G350-6. 57894
    View PubMed
  272. Gaisano HY, Reilly W, Go VL, Olivero D, Miller LJ. Large molecular forms of cholecystokinin circulating in humans. Pancreas. 1986; 1(2):148-53. 1051680
    View PubMed
  273. Tietz PS, Thistle JL, Miller LJ, LaRusso NF. Development and validation of a method for measuring the glycine and taurine conjugates of bile acids in bile by high-performance liquid chromatography. J Chromatogr. 1984 Dec 12; 336(2):249-57. 52949
    View PubMed
  274. Miller LJ. Characterization of cholecystokinin receptors on human gastric smooth muscle tumors. Am J Physiol. 1984 Oct; 247(4 Pt 1):G402-10. 53683
    View PubMed
  275. Miller LJ, Jardine I, Weissman E, Go VL, Speicher D. Characterization of cholecystokinin from the human brain. J Neurochem. 1984 Sep; 43(3):835-40. 52106
    View PubMed
  276. Miller LJ, Bartholomew LG, Dozois RR, Dahlin DC. Adenocarcinoma of the rectum arising in a hamartomatous polyp in a patient with Peutz-Jeghers syndrome. Dig Dis Sci. 1983 Nov; 28(11):1047-51. 49582
    View PubMed
  277. Miller LJ, Reilly WM, Rosenzweig SA, Jamieson JD, Go VLW. A soluble interaction between dibutyryl cyclic guanosine 3':5'-monophosphate and cholecystokinin: a possible mechanism for the inhibition of cholecystokinin activity. Gastroenterology. 1983 Jun; 84:1505-1511. 48579
    View PubMed
  278. Miller LJ. Small intestinal manifestations of diabetes mellitus. Yale Journal of Biology & Medicine. 1983 May-Jun; 56(3):189-93. 50453
    View PubMed
  279. McCullough AJ, Miller LJ, Service FJ, Go VL. Effect of graded intraduodenal glucose infusions on the release and physiological action of gastric inhibitory polypeptide. J Clin Endocrinol Metab. 1983 Feb; 56(2):234-41. 47820
    View PubMed
  280. Go VL, Miller LJ. The role of gastrointestinal hormones in the control of postprandial and interdigestive gastrointestinal function. Scand J Gastroenterol Suppl. 1983; 82:135-42. 48349
    View PubMed
  281. Rosenzweig SA, Miller LJ, Jamieson JD. Identification and localization of cholecystokinin binding sites on rat pancreatic plasma membranes and acinar cells: a biochemical and morphological study. J Cell Biol. 1983; 96:1288-1297. 50451
    View PubMed
  282. Miller LJ, Reilly WM, Rosenweig SA, Jamieson JD, Go VLW. The mechanism by which dibutyryl cyclic GMP antagonizes the action of cholecystokinin. Gastroenterology. 1983; 84:1637-1639. 50452
    View PubMed
  283. Owyang C, Miller LJ, Malagelada JR, Go VL. Nutrient and bowel segment dependency of human intestinal control of gastric secretion. Am J Physiol. 1982 Nov; 243(5):G372-6. 46504
    View PubMed
  284. Kelly DG, Miller LJ, Malagelada JR, Huizenga KA, Markowitz H. Giant hypertrophic gastropathy (Ménétrier's disease): pharmacologic effects on protein leakage and mucosal ultrastructure. Gastroenterology. 1982 Sep; 83(3):581-9. 46008
    View PubMed
  285. Owyang C, Miller LJ, DiMagno EP, Mitchell JC 3rd, Go VL. Pancreatic exocrine function in severe human chronic renal failure. Gut. 1982 May; 23(5):357-61. 45712
    View PubMed
  286. Rees WD, Malagelada JR, Miller LJ, Go VL. Human interdigestive and postprandial gastrointestinal motor and gastrointestinal hormone patterns. Dig Dis Sci. 1982 Apr; 27(4):321-9. 45312
    View PubMed
  287. Miller LJ, Malagelada JR, Taylor WF, Go VL. Intestinal control of human postprandial gastric function: the role of components of jejunoileal chyme in regulating gastric secretion and gastric emptying. Gastroenterology. 1981 Apr; 80(4):763-9. 42491
    View PubMed
  288. Miller LJ, Rosenzweig SA, Jamieson JD. Preparation and characterization of a probe for the cholecystokinin octapeptide receptor, N-alpha-125-I-desaminotyrosyl) CCK-8, and its interactions with pancreatic acini. J Biol Chem. 1981; 256:12417-12423. 44230
    View PubMed
  289. Miller LJ, Malagelada JR, Longstreth GF, Go VL. Dysfunctions of the stomach with gastric ulceration. Dig Dis Sci. 1980 Nov; 25(11):857-64. 41254
    View PubMed
  290. McGill DB, Miller LJ, Carney JA, Phillips SF, Go VLW, Schutt AJ. Hormonal diarrhea due to pancreatic tumor. Gastroenterology. 1980 Sep; 79:571-582. 40608
  291. Miller LJ, Owyang C, Malagelada JR, Gorman CA, Go VL. Gastric, pancreatic, and biliary responses to meals in hyperthyroidism. Gut. 1980 Aug; 21(8):695-700. 40991
    View PubMed
  292. Miller LJ, Resseguie LJ, Taylor WF, Malagelada JR. Cholecystectomy and gastric ulcer--an etiologic relationship? Mayo Clin Proc. 1980 Apr; 55(4):255-7. 39966
    View PubMed
  293. Rees WD, Miller LJ, Malagelada JR. Dyspepsia, antral motor dysfunction, and gastric stasis of solids. Gastroenterology. 1980 Feb; 78(2):360-5. 39712
    View PubMed
  294. Krawisz BR, Miller LJ, DiMagno EP, Go VL. In the absence of nutrients, pancreatic-biliary secretions in the jejunum do not exert feedback control of human pancreatic or gastric function. Journal of Laboratory & Clinical Medicine. 1980 Jan; 95(1):13-8. 39719
    View PubMed
  295. Owyang C, Miller LJ, DiMagno EP, Brennan LA Jr, Go VL. Gastrointestinal hormone profile in renal insufficiency. Mayo Clin Proc. 1979 Dec; 54(12):769-73. 38486
    View PubMed
  296. Owyang C, Miller LJ, Lie JT, Fleming CR. Takayasu's arteritis in Crohn's disease. Gastroenterology. 1979 Apr; 76:825-828. 37582
    View PubMed
  297. Miller LJ, Clain JE, Malagelada JR, Go VL. Control of human postprandial pancreatic exocrine secretion: a function of the gastroduodenal region. Dig Dis Sci. 1979 Feb; 24(2):150-4. 39255
    View PubMed
  298. Miller LJ, Malagelada JR, Go VL. Intestinal nutrient influence on the enteroinsular axis. J Clin Endocrinol Metab. 1978 Nov; 47(5):1009-14. 36063
    View PubMed
  299. Miller LJ, Gorman CA, Go VL. Gut-thyroid interrelationships. Gastroenterology. 1978 Nov; 75(5):901-11. 36069
    View PubMed
  300. Miller LJ, Malagelada JR, Go VL. Postprandial duodenal function in man. Gut. 1978 Aug; 19(8):699-736. 1312414
    View PubMed
  301. Miller LJ, Thistle JL, Payne WS, Gaffey TA, O'Duffy JD. Crohn's disease involving the esophagus and colon. Case report. Mayo Clin Proc. 1977 Jan; 52(1):35-8. 33381
    View PubMed
  302. Gordon SJ, Miller LJ, Haeffner LJ, Kinsey MD, Kowlessar OD. Abnormal intestinal bile acid distribution in azotemic man: a possible role in the pathogenesis of uremic diarrhea. Gut. 1976; 17:58-67. 33193
    View PubMed
  303. Miller LJ, Gordon SJ, Haeffner LJ, Saukkonen JJ, Kinsey MD, Kowlessar OD. Bile acid abnormalities in uremic man. Gastroenterology. 1974; 66:746. 29802